Research progress of novel small molecule anti-VEGF drug Brolucizumab in the treatment of diabetic macular edema
10.3980/j.issn.1672-5123.2022.8.08
- VernacularTitle:新型小分子抗VEGF药物Brolucizumab治疗糖尿病性黄斑水肿的研究进展
- Author:
Ke-Ke HU
1
;
Tong WU
1
;
Yan-Nian HUI
1
;
Hong-Jun DU
1
Author Information
1. Department of Ophthalmology, Eye Institute of PLA, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
Brolucizumab;
diabetic macular edema;
vascular endothelial growth factor(VEGF);
efficacy;
safety
- From:
International Eye Science
2022;22(8):1277-1280
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic macular edema(DME)has become the leading cause of vision loss in patients with diabetes. Currently, intravitreal injection of anti-vascular endothelial growth factor(VEGF)therapy is the first-line treatment for DME. However, the economic burden and related complications brought by frequent injections should not be ignored. Therefore, the drugs with longer-lasting effects and longer injection intervals must be explored. Brolucizumab is a single-chain antibody fragment(scFv)with a high affinity for VEGF. Compared with other available anti-VEGFs, it has the characteristics of smaller molecular weight, higher tissue permeability and durable therapeutic effect. Clinical studies and real-world evidences showed that Brolucizumab is non-inferior to aflibercept in improving visual acuity in patients with DME. And Brolucizumab is more effective in regressing intra-retinal fluid and reducing central foveal thickness(CSFT)with longer injection interval. At the same time, Brolucizumab has a low incidence of adverse events and favourable safety after intraocular injection. This article reviews the latest progress of Brolucizumab in the treatment of DME.
